Table 1.
Patient characteristics by the number of biochemical markers out of target
| Variables | Levels | None out of target (n = 5224) | 1 out of target (n = 9624) | 2 out of target (n = 9599) | 3 out of target (n = 1774) | All patients (n = 26 221) |
|---|---|---|---|---|---|---|
| Age group (%) | 0–29 years | 0.5 | 1.1 | 3.6 | 4.2 | 2.1 |
| 30–39 years | 2.6 | 4.5 | 8.9 | 9.9 | 6.1 | |
| 40–49 years | 7.5 | 11.0 | 16.6 | 18.3 | 12.8 | |
| 50–59 years | 16.1 | 20.3 | 24.5 | 25.1 | 21.4 | |
| 60–64 years | 11.6 | 12.7 | 12.3 | 11.8 | 12.3 | |
| 65–69 years | 13.2 | 13.1 | 11.5 | 10.0 | 12.3 | |
| 70–79 years | 29.5 | 22.9 | 15.6 | 14.4 | 21.0 | |
| ≥80 years | 18.9 | 14.3 | 7.0 | 6.4 | 12.0 | |
| Sex (%) | Men | 55.1 | 53.2 | 53.3 | 56.5 | 53.9 |
| Women | 44.9 | 46.8 | 46.7 | 43.5 | 46.1 | |
| Race (%) | White | 61.9 | 53.0 | 47.6 | 45.2 | 52.3 |
| African American | 29.3 | 37.8 | 43.0 | 47.9 | 38.7 | |
| Native American | 2.6 | 3.0 | 3.1 | 2.5 | 2.9 | |
| Asian | 4.6 | 4.8 | 4.8 | 3.3 | 4.7 | |
| Other/unknown | 1.5 | 1.4 | 1.4 | 1.2 | 1.4 | |
| Comorbid conditions (%) | ASHD | 42.5 | 38.2 | 33.6 | 31.6 | 36.9 |
| CHF | 44.6 | 42.7 | 41.9 | 39.0 | 42.5 | |
| COPD | 17.7 | 17.4 | 16.6 | 15.6 | 17.0 | |
| CVA | 17.5 | 16.7 | 13.6 | 14.4 | 15.6 | |
| Diabetes | 62.1 | 59.6 | 54.5 | 47.1 | 57.3 | |
| Vintage (%) | 12–24 months | 30.2 | 25.0 | 20.4 | 15.5 | 23.7 |
| 25–48 months | 36.2 | 33.9 | 31.3 | 25.1 | 32.8 | |
| ≥49 months | 33.6 | 41.1 | 48.4 | 59.4 | 43.5 | |
| Albumin, g/dL | Mean (SD) | 3.85 (0.34) | 3.86 (0.35) | 3.90 (0.34) | 3.90 (0.36) | 3.87 (0.35) |
| Hemoglobin, g/dL | Mean (SD) | 12.36 (0.85) | 12.34 (0.91) | 12.37 (0.94) | 12.41 (0.96) | 12.36 (0.91) |
| Kt/V | Mean (SD) | 1.71 (0.25) | 1.68 (0.25) | 1.63 (0.24) | 1.60 (0.23) | 1.66 (0.25) |
| PTH, pg/mL | Mean (SD) | 228 (40.8) | 341 (243) | 589 (486) | 702 (652) | 434 (403) |
| Calcium, mg/dL | Mean (SD) | 9.56 (0.38) | 9.59 (0.47) | 9.59 (0.61) | 9.83 (1.13) | 9.60 (0.58) |
| Phosphate, mg/dL | Mean (SD) | 4.64 (0.51) | 5.09 (0.96) | 6.29 (1.26) | 6.60 (1.21) | 5.54 (1.26) |
| Event rate (%) | Death | 24.3 | 23.9 | 21.5 | 24.2 | 23.1 |
| Composite | 43.0 | 43.6 | 45.1 | 47.6 | 44.3 | |
| Any MBD-directed therapy (%) | Any vitamin D | 85 | 83 | 85 | 79 | 84 |
| Any phosphate binder | 90 | 92 | 95 | 95 | 93 | |
| Any non-calcium-containing phosphate binder | 52 | 62 | 74 | 75 | 65 | |
| Any calcium-containing phosphate binder | 55 | 53 | 52 | 52 | 53 | |
| Any cinacalcet | 11 | 21 | 35 | 37 | 25 |
Only selected comorbidities are shown, including ASHD, atherosclerotic heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident. Groups included in this table are mutually exclusive and are used to construct definitions of ≥1 Out of Target, ≥2 Out of Target and ≥3 Out of Target. Because information about MBD-directed therapy is summarized on a monthly basis as yes/no, calcium and non-calcium-containing phosphate binder categories are not mutually exclusive.